首頁 > 市場調查報告書 > 製藥

植物來源藥物市場規模、佔有率和成長分析：按產品類型、原料、藥物類別、應用、給藥途徑、最終用戶和地區分類－2026-2033年產業預測

市場調查報告書

商品編碼

2079932

植物來源藥物市場規模、佔有率和成長分析：按產品類型、原料、藥物類別、應用、給藥途徑、最終用戶和地區分類－2026-2033年產業預測

Botanical and Plant Derived Drugs Market Size, Share, and Growth Analysis, By Product Type, By Source, By Drug Class, By Application, By Route of Administration, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2026年06月30日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2024 年全球植物來源市場價值為 387 億美元，預計到 2025 年將成長至 419.9 億美元，到 2033 年將成長至 806.5 億美元，在預測期（2026-2033 年）內複合年成長率為 8.5%。

植物來源產品的法規核准正推動植物來源市場顯著成長，並增強投資者和醫療專業人士的信心。這種正式的監管批准為保險覆蓋鋪平了道路，刺激了研發投資，並加快了產品開發進程。尤其值得一提的是，大麻素在特定醫療應用中的療效已得到認可，這促使大量臨床試驗湧現，探索其在包括皮膚病學和腫瘤學在內的各個領域的治療潛力。因此，製藥公司正與農業科技公司合作取得原料，而保險公司也正在擴大這些創新療法的承保範圍。這一趨勢正在開闢新的收入來源，並改善全球患者獲得這些療法的機會，反映了醫療保健格局的變革性轉變。

全球植物來源市場促進因素

消費者對天然和植物來源療法的興趣日益濃厚，促使製藥公司進一步探索草藥資源，並透過增加植物來源產品來豐富產品系列。許多患者將自身健康放在首位，尋求合成藥物的替代方案，他們認為這些天然療法更安全，更有益於整體。這種需求的成長促使製造商大力投資於植物來源活性成分的研發。因此，醫療保健專業人員擴大將草藥納入治療方案，從而創造了開立這些天然產品的機會。反過來，這又吸引了潛在投資者和合作夥伴的更多關注，促成了合作，加速了產品上市，並推動了整體市場成長。

全球植物來源市場限制因素

由於植物藥的臨床檢驗要求十分嚴格，全球植物來源市場面臨嚴峻挑戰。這些要求包括全面的安全性和有效性測試。繁瑣的測試流程延長了產品研發週期，增加了生產成本。此外，植物化學的複雜性也需要多種分析技術和大規模的樣本大小，這進一步增加了新植物來源療法上市的監管門檻。因此，資源有限的小規模創新公司可能會猶豫是否將新的植物來源產品推向市場。這種緩慢的產品上市不僅阻礙了市場成長，也削弱了投資者對新興企業的信心。

全球植物來源藥物市場趨勢

全球植物來源市場正經歷著由植物性因組學加速發展所驅動的重大趨勢。基因組研究和高通量定序技術的創新使企業能夠快速識別和開發生物活性化合物。合成生物學的進步也為此提供了有力支持，它使得在微生物宿主中複製複雜的植物代謝途徑成為可能，從而減少了對傳統農業資源的依賴。這項變革最終將透過以下方式拓展永續藥物的可能性：提高不同治療領域永續的穩定性；刺激創業投資；促進生技公司與學術機構之間的合作；並鼓勵大型製藥企業將植物來源化合物納入其研發。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太國家
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲國家

競爭資訊

前五大公司對比
主要公司2025年的市場定位
主要市場公司採取的策略
近期市場趨勢
企業市場占有率分析，2025 年
主要公司的完整公司簡介
- 公司詳情
- 產品系列分析
- 按細分市場進行企業市佔率分析
- 銷售收入年比比較（2023-2025 年）

主要公司簡介

Bayer AG
Indena SpA
Schwabe Group
Bionorica SE
Tilray Brands, Inc.
Jazz Pharmaceuticals plc
PhytoTech Therapeutics Ltd.
Aboca SpA Societa Agricola
Martin Bauer Group
Euromed SA
Hunan Nutramax Inc.
Xi'an Jiaotong Pharmaceuticals Group
Sami-Sabinsa Group Limited
Himalaya Global Holdings Ltd.
Yunnan Baiyao Group Co., Ltd.
Tasly Pharmaceutical Group Co., Ltd.
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
MediHerb Pty Ltd.
CK Life Sciences International Holdings Inc.
PuraPharm Corporation Limited

結論與建議

簡介目錄

Product Code: SQMIG35I2902

Global Botanical And Plant Derived Drugs Market size was valued at USD 38.70 Billion in 2024 and is poised to grow from USD 41.99 Billion in 2025 to USD 80.65 Billion by 2033, growing at a CAGR of 8.5% during the forecast period (2026-2033).

The regulatory approval of plant-based products is driving significant growth in the botanical and plant-derived drugs market, instilling confidence among investors and healthcare professionals. This formal recognition by regulatory bodies paves the way for reimbursement opportunities, fostering research investments and accelerating product development timelines. Notably, the validation of cannabinoids for specific medical applications has prompted a surge in clinical trials exploring their therapeutic potential in various fields, including dermatology and oncology. Consequently, pharmaceutical companies are forming partnerships with agricultural technology firms for material sourcing, while insurers are increasingly covering these innovative therapies. This development unlocks new revenue streams and enhances accessibility to these treatments for patients worldwide, reflecting a transformative shift in the healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Botanical And Plant Derived Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Botanical And Plant Derived Drugs Market Segments Analysis

Global botanical and plant derived drugs market is segmented by product type, source, drug class, application, route of administration, end user and region. Based on product type, the market is segmented into botanical drugs and plant-derived drugs. Based on source, the market is segmented into medicinal plants, herbs, flowers & fruits, roots & rhizomes and others. Based on drug class, the market is segmented into anticancer drugs, anti-inflammatory drugs, cardiovascular drugs, antimicrobial drugs, CNS drugs and others. Based on application, the market is segmented into oncology, cardiovascular disorders, infectious diseases, neurological disorders, pain management and others. Based on route of administration, the market is segmented into oral, topical, injectable and others. Based on end user, the market is segmented into hospitals, specialty clinics, pharmaceutical companies and research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Botanical And Plant Derived Drugs Market

The rising consumer interest in natural and plant-based remedies propels pharmaceutical companies to delve deeper into herbal sources, aiming to diversify their portfolios with more plant-derived medicines. Many patients, prioritizing their health and seeking alternatives to synthetic drugs, perceive these natural options as safer and more beneficial for holistic well-being. This escalating demand prompts manufacturers to invest heavily in the research and development of plant-based active ingredients. Consequently, healthcare providers are more inclined to incorporate herbs into treatment plans, fostering opportunities to prescribe these natural products. As a result, manufacturers experience heightened interest from potential investors and partners, leading to collaborative efforts that enhance product launches and drive overall market growth.

Restraints in the Global Botanical And Plant Derived Drugs Market

The Global Botanical and Plant-Derived Drugs market faces significant challenges due to rigorous clinical validation requirements for botanical medicines, which demand comprehensive safety and efficacy testing. This extensive testing process prolongs product development timelines and escalates costs for manufacturers. Additionally, the intricate nature of phytochemistry calls for diverse analytical testing methods and larger sample sizes, intensifying regulatory hurdles for introducing new plant-based treatments. Consequently, smaller, innovative companies with limited resources may be deterred from entering the market with new botanical options. This slow rate of product introduction not only hampers market growth but also diminishes investor confidence in emerging ventures.

Market Trends of the Global Botanical And Plant Derived Drugs Market

The Global Botanical and Plant Derived Drugs market is witnessing a significant trend driven by the acceleration of plant genomics. Innovations in genomic research and high-throughput sequencing technologies are enabling companies to rapidly identify and develop bioactive compounds. This transformation is complemented by advancements in synthetic biology, allowing the replication of intricate plant pathways in microbial hosts, thereby diminishing reliance on traditional agricultural sources. This shift enhances supply chain stability across diverse therapeutic areas and encourages venture capital investment, fosters collaborations between biotech firms and academic institutions, and drives large pharmaceutical companies to integrate plant-based compounds into their research, ultimately broadening the potential for sustainable pharmaceuticals.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index 2025
PESTEL Analysis
Regulatory Landscape
Disease Epidemiology

Global Botanical and Plant Derived Drugs Market Size by Product Type & CAGR (2026-2033)

Market Overview
Botanical Drugs
Plant-Derived Drugs

Global Botanical and Plant Derived Drugs Market Size by Source & CAGR (2026-2033)

Market Overview
Medicinal Plants
Herbs
Flowers & Fruits
Roots & Rhizomes
Others

Global Botanical and Plant Derived Drugs Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Anticancer Drugs
Anti-Inflammatory Drugs
Cardiovascular Drugs
Antimicrobial Drugs
CNS Drugs
Others

Global Botanical and Plant Derived Drugs Market Size by Application & CAGR (2026-2033)

Market Overview
Oncology
Cardiovascular Disorders
Infectious Diseases
Neurological Disorders
Pain Management
Others

Global Botanical and Plant Derived Drugs Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Topical
Injectable
Others

Global Botanical and Plant Derived Drugs Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Specialty Clinics
Pharmaceutical Companies
Research Institutes

Global Botanical and Plant Derived Drugs Market Size & CAGR (2026-2033)

North America (Product Type, Source, Drug Class, Application, Route of Administration, End User)
- US
- Canada
Europe (Product Type, Source, Drug Class, Application, Route of Administration, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product Type, Source, Drug Class, Application, Route of Administration, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product Type, Source, Drug Class, Application, Route of Administration, End User)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Product Type, Source, Drug Class, Application, Route of Administration, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Indena S.p.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Schwabe Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bionorica SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tilray Brands, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Jazz Pharmaceuticals plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PhytoTech Therapeutics Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aboca S.p.A. Societa Agricola
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Martin Bauer Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Euromed S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hunan Nutramax Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Xi'an Jiaotong Pharmaceuticals Group
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sami-Sabinsa Group Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Himalaya Global Holdings Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Yunnan Baiyao Group Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tasly Pharmaceutical Group Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MediHerb Pty Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CK Life Sciences International Holdings Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PuraPharm Corporation Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments